Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Utah
About this trial
The goal of this clinical trial is to learn if using topical tretinoin will help patients with solid tumors who are experiencing an acneiform rash as a side effect of their treatment.
Researchers will compare the use of tretinoin on one side of the face to the use of a placebo on the other side of the face to see if there is an impact.
Eligibility criteria
Qualifiers
Participant aged ≥ 18 years
Histologically confirmed solid tumor.
Radiologically confirmed locally advanced or metastatic disease.
Eligible for and willing to receive treatment with panitumumab or cetuximab as standard-of-care.
Disqualifiers
Treatment with an anti-EGFR agent within 90 days of registration.
Pre-existing facial rash that per the treating investigator would preclude the ability to assess response to topical tretinoin.
The diagnosis of another malignancy within ≤ 2 years before study enrollment, except for those considered to be adequately treated with no evidence of disease or symptoms and/or will not require therapy during the study duration (i.e., basal cell or squamous cell skin cancer, carcinoma in situ of the breast, bladder or of the cervix, or low-grade prostate cancer with Gleason Score ≤ 6).
Any other condition that would, in the Investigator's judgment, contraindicate the participant's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
Trial design
Treatments tested in this trial
- Topical Tretinoin
- Placebo
Treatment groups
25 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov